TA-8995: Its Use in Patients With Mild Dyslipidaemia (TULIP)

PHASE2CompletedINTERVENTIONAL
Enrollment

364

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

July 31, 2014

Study Completion Date

July 31, 2014

Conditions
Dyslipidemia
Interventions
DRUG

TA-8995

DRUG

Atorvastatin

DRUG

Rosuvastatin

DRUG

TA-8995 0mg (placebo)

DRUG

Placebo Statin

Trial Locations (17)

Unknown

H:S Amager Hospital, Copenhagen

Sydvestjysk Sygehus, Esbjerg

Herlev University Hospital, Herlev

Hvidovre Hospital, Hvidovre

Regionshopitalet - Silkeborg, Silkeborg

EB FlevoResearch B.V, Almere Stad

Andromed Amsterdam, Amsterdam

Andromed Leiden, Amsterdam

Academic Medical Centre, Amsterdam-Zuidoost

Andromed Breda B.V, Breda

Andromed Eindhoven, Eindhoven

Andromed Noord B.V, Groningen

Andromed Zoetermeer, Leiderdorp

Andromed Rotterdam BV, Rotterdam

Albert Schweitzer Ziekenhuis, Sliedrecht

Andromed Oost, Velp

Praktijk Zwijndrecht, Zwijndrecht

All Listed Sponsors
lead

Xention Ltd

INDUSTRY

NCT01970215 - TA-8995: Its Use in Patients With Mild Dyslipidaemia (TULIP) | Biotech Hunter | Biotech Hunter